Customer Centricity in Pharma & Life Sciences

What customer centricity actually means

Customer centricity is a business philosophy in which the organisation is designed around what its customers value, and success is measured by customer outcomes rather than by internal output. In classical marketing theory this is the marketing concept — one of five management philosophies alongside the production, product, selling and societal marketing concepts. It is distinguished from the selling concept, which starts with what the company has made and asks how to persuade someone to take it. Both can generate revenue; only one generates preference.

The distinction matters in pharmaceuticals more than the abstraction suggests, because the industry's economics have historically rewarded the selling concept. A differentiated molecule with patent protection, guideline inclusion and reimbursement does not strictly need the prescriber to enjoy the experience of being sold to. What has changed is that fewer products are differentiated enough for that to hold, and that the prescriber now has the practical means to decline the interaction entirely.

What is a customer focused model?

A customer focused model is an operating design in which structure, metrics, incentives and decision rights are organised around customer segments and their journeys rather than around products or internal functions. In practice that means three concrete things: someone owns the customer rather than only the brand; the customer's experience is measured directly rather than inferred from activity; and the organisation can change what it does in response to that measurement without a reorganisation. Most pharmaceutical organisations satisfy the first condition partially, the second rarely and the third almost never — which is why customer centricity programmes so often produce a new set of slides and the same commercial behaviour.

The perception gap, and the mechanism that produces it

Across every study that asks both sides the same question, sellers rate the relationship substantially higher than customers do. Deloitte found 82% of life sciences executives satisfied with their engagement strategy against 28% of healthcare professionals who felt it met their needs. Bain found representatives overvaluing personal relationships — more than 50% rating them important against 29% of physicians — while physicians were 12.5 times more likely to name faster response times as the key opportunity. Nobody in these studies is being dishonest. The seller simply cannot see what the customer values, because nothing in the commercial measurement system reports it.
 

The constructive finding sits alongside these. Accenture reported that 88% of healthcare professionals would be roughly twice as likely to meet with representatives if interactions matched the standard of their best pharmaceutical relationship, that 35% became more likely to accept future meetings after a positive interaction, and that 41% became more likely to open a company's emails. The willingness is present. What is missing is a mechanism that tells the organisation which interactions were good.

What is the purpose of customer centricity?

The commercial purpose is to secure preference in a market where access is scarce and differentiation is narrowing. When a physician will see only a limited number of companies, being one of them is worth more than any incremental improvement in reach or frequency. Bain found that 77% of US prescribers say peer advocacy plays a significant role in treatment selection, and that around 40% of physician advocacy for a drug is directly linked to customer experience and loyalty. Customer centricity is therefore not a values statement. It is the mechanism by which a company earns a place on a shortlist it does not control.
This is worth stating in commercial rather than ethical terms, because the ethical framing is precisely what causes customer centricity programmes to be deprioritised when a quarter goes badly. If it is a values initiative, it competes with the number. If it is the route to being one of the three companies a physician will still see — when Veeva Pulse data shows access has fallen to around 45% and half of accessible physicians restrict engagement to three companies or fewer — then it is the number.

Who is “the customer” in pharma?

There are at least five, with materially different and sometimes conflicting interests: patients, prescribers, provider organisations, payers and the trade. The commercial consequence is that “customer centricity” is meaningless until you name which customer a given decision is centred on. One framing that has aged well describes the United States market as roughly 200 million consumers, 200,000 relevant physicians, around 200 integrated delivery networks and about 200 highly influential payers — four populations differing by six orders of magnitude, each requiring a different operating model.
 

The trade row is the one most often missed and the one that matters most in India and comparable markets. A brand strategy that is exquisitely centred on the prescriber and indifferent to stockist economics will fail at the point of dispensing, and the failure will be diagnosed as a promotion problem. Customer centricity that stops at the prescriber is prescriber centricity, which is a narrower and more comfortable thing to attempt.

Patient centricity and customer centricity are not the same discipline

Patient centricity means designing products, trials, services and information around the person who takes the medicine. Customer centricity means designing the commercial model around whoever makes and influences the decision — which, in most markets and most therapy areas, is not the patient. The two are complementary and frequently confused, and conflating them produces patient-facing initiatives that never change commercial behaviour, or commercial programmes that borrow patient-centric language without any patient involvement.

A practical reconciliation: patient centricity sets the standard for what a company should be trying to achieve, and customer centricity is how it earns the right to achieve it through people it does not employ and cannot instruct. Companies that treat them as the same programme usually end up doing neither well.

Why pharma is structurally harder than other industries

Six structural features make customer centricity genuinely harder in life sciences than in retail, banking or technology: the buyer, the payer and the user are usually three different people; promotional content must clear medical, legal and regulatory review before it can be personalised; the company frequently has no direct relationship with the end user; the decision cycle spans years; the data that would prove customer impact is often unavailable at the individual level; and the organisation is structured around brands rather than customers. These are constraints, not excuses — but a customer centricity programme designed as if the industry were consumer retail will fail on all six.
 

The last row is the one that most reliably determines whether a programme succeeds. When six brand teams each hold a share-of-voice target against the same physician, the aggregate experience is nobody's responsibility and the physician's inbox is the place where the strategy is actually resolved. Assigning ownership of total contact volume is the least popular and most effective intervention available.

A maturity model you can locate yourself on

Five stages, distinguished by where the customer's view enters the organisation. At stage one it does not; at stage five it governs resource allocation. Most large pharmaceutical companies are at stage two or three — they conduct customer research and have segmented their customers, but the research reaches strategy rather than execution, and the segmentation drives message selection rather than resource allocation. Locating yourself accurately matters more than aspiring accurately, because the interventions that move you from two to three are different from the ones that move you from three to four.

A note on stage five. The defining behaviour is not doing more for customers; it is doing less where the evidence says less is better, and moving the resource. Almost every organisation can point to an initiative that added something for customers. Very few can point to a decision where customer evidence caused them to reduce activity against a segment and redeploy the capacity. That asymmetry is the most reliable diagnostic in the whole model.

Measure the customer, not your activity

The practical definition of a customer-centric organisation is one in which customer-generated metrics carry the same authority as seller-generated metrics in resource decisions. Seller-generated metrics — calls, coverage, frequency, content deployed, share of voice — describe effort. Customer-generated metrics — response initiated by the customer, content depth reached, meeting acceptance rate over time, unprompted questions asked, willingness to recommend — describe whether the effort landed. Most pharmaceutical dashboards contain twenty of the first and none of the second, which is the entire mechanism behind the 82% against 28% gap.

Start with response time. It requires no new research instrument, it is measurable from existing systems, the evidence that customers weight it heavily is unusually strong, and it is the rare customer-centricity intervention that reduces cost rather than adding it. If a customer centricity programme needs a first proof point that survives finance scrutiny, this is it.

A 90-day path to a customer-centric commercial operation

Customer centricity programmes usually fail by being too large. The sequence below is deliberately narrow: it produces one customer-generated metric on the main dashboard, one owner of total experience, and one demonstrated improvement, inside a quarter. That is enough to make the next phase fundable.

1. Days 1–10: name the customer for each decision. List the ten commercial decisions your organisation makes most often and write down which customer each is centred on — patient, prescriber, provider organisation, payer or trade. Where the answer is “all of them”, the decision is not customer-centred. This exercise takes a week and reliably produces uncomfortable clarity.
2. Days 11–20: audit the dashboard. Count the metrics your commercial leadership reviews monthly, and classify each as seller-generated or customer-generated. In most organisations the ratio is above twenty to zero. That count is your baseline and your argument.
3. Days 21–30: instrument response time. Measure the interval from a customer's question to a substantive answer, across medical enquiries, commercial requests and field follow-ups. Do not improve it yet — establish the distribution, including the tail, because the tail is what customers remember.
4. Days 31–45: measure total contact volume per customer across all brands. Nobody usually holds this number. Produce it, distribute it by physician, and identify the top decile of contacted physicians. Compare that list against your access data. The overlap between “most contacted” and “declining access” is usually the most persuasive slide anyone will produce that year.
5. Days 46–55: run direct customer research with a consistent instrument. Ask a small, repeatable set of questions of a representative sample: whether engagement meets their needs, what would improve it, response time perception, and share of their accepted shortlist. Design it to be repeated quarterly rather than to be comprehensive once.
6. Days 56–70: appoint an owner of total customer experience. One named person, with authority over aggregate contact volume across brands, and a mandate that includes reducing it. Without the authority to reduce, the role becomes a coordinator and the volume continues to rise.
7. Days 71–80: fix response time in one therapy area. Choose the area with the worst tail, redesign the enquiry path, and measure the change. This is your proof point: it is fast, it is cheap, it is measurable, and the evidence that customers value it is stronger than for any other single intervention.
8. Days 81–90: put one customer-generated metric on the leadership dashboard permanently. Response time is the natural first candidate. The objective is not the metric itself but the precedent — that a number the customer generates now sits alongside the numbers the organisation generates about itself, and is reviewed with the same seriousness.

Steps two and six are the ones that determine whether anything persists. The dashboard audit creates the argument, and the ownership appointment creates the mechanism. A programme that runs the research but appoints nobody produces a well-evidenced description of a problem that continues.

What changes in India and comparable markets

Four things. The trade is a genuine customer rather than a distribution channel, and ignoring it breaks the strategy at the point of dispensing. Growth is price and mix led — 10.3% value against 0.8% volume in April 2026 — so preference matters more than reach. There is no prescriber-level prescription data, so customer-centric measurement must be built on proxies and direct research rather than on behavioural attribution. And the working digital channel is WhatsApp, which makes relevance a compliance question as well as a commercial one, since consent must be enforced at the point of sending.

The last row is not a rhetorical flourish. Personalisation applied to a duplicated, stale customer record produces the specific experience customers describe as spam — the same company contacting them repeatedly as if they were several different people, with content that does not reflect what they have already been sent. In our audits the discrepancy rate in pharma CRM doctor records runs around 57%, and it is a common root cause of experiences that the organisation believes are personalised. We cover the remedy in doctor data validation and enrichment.

Where Multiplier AI fits — and where it does not

Customer centricity is mostly an organisational discipline, and most of it is not something a vendor can sell you. The honest boundary:

Do not shortlist us if

• You are looking for a customer centricity transformation programme. Operating model redesign, governance and cultural change are consulting engagements — ZS, Bain, Deloitte, Accenture and others do this work. We do not.
• Your gap is ownership and incentives. If nobody owns total customer experience and no incentive reflects it, no platform will change the outcome. That is a leadership decision and it costs nothing but resolve.
• You need customer research capability. Direct research with a consistent instrument is a market research discipline. Buy it from a research agency.
• You are at maturity stage one. If customer input reaches the organisation only as field anecdote, start with research and dashboard change rather than with technology.

Do shortlist us if

• Personalisation is failing because the customer record is wrong. Our GenAI Doctor Data Platform profiles physicians across more than 100 parameters with continuous verification, which is the precondition for any experience that feels personal rather than automated.
• Relevance is the constraint and content is the bottleneck. Our Hyper Personalized Content Platform assembles and delivers approved content across email, WhatsApp and social by cohort and behaviour, which is what relevance looks like operationally within MLR constraints.
• You need consent and frequency enforced at send. In markets where WhatsApp is the working channel, relevance and compliance are the same control. Ours runs at delivery, not in reporting.
• You want measured improvement in the interaction itself. Published outcomes from our Indian deployments include a minimum 120% increase in time spent in the doctor's cabin and a 37% increase in medical representative efficiency — both customer-experience outcomes as much as productivity ones.

The mistakes that make customer centricity a slogan

• Not naming the customer. A strategy centred on patients, prescribers, payers and the trade simultaneously is centred on none of them. Name the customer for each decision.
• Measuring only your own activity. An organisation whose dashboard contains twenty seller-generated metrics and none generated by customers will believe it is performing well whenever activity is high.
• Treating it as a values programme. Framed ethically, it competes with the number and loses. Framed as the route to a shortlist you do not control, it is the number.
• Personalising on a broken customer record. Personalisation applied to duplicated data produces precisely the experience customers describe as spam.
• Adding without subtracting. Every customer-centricity initiative that adds a touchpoint without removing one increases the volume customers already report as excessive.
• Leaving total contact volume unowned. When each brand holds its own share-of-voice target, the physician's inbox becomes where strategy is actually resolved.
• Confusing patient centricity with customer centricity. They are complementary disciplines with different owners, activities and measures. Running one while claiming the other is common and visible from outside.

Key takeaways

• Customer centricity is the marketing concept in classical terms — designing the business around what customers value rather than around what you produce. It is the philosophy behind “the customer is king.”
• The defining evidence is a perception gap: 82% of life sciences executives satisfied with customer engagement against 28% of HCPs who say it meets their needs.
• The mechanism is measurement. Commercial dashboards are almost entirely seller-generated, so the organisation cannot see what the customer values.
• Physicians are 12.5 times more likely than representatives to name faster response times as the key opportunity, while representatives overvalue personal relationships. Response time is the highest-yield metric to add.
• Pharma has five customer types with conflicting interests. Name which customer each decision is centred on, and include the trade in emerging markets.
• Patient centricity and customer centricity are complementary but distinct disciplines with different owners, activities and measures.
• Stage five maturity is defined by reducing activity where evidence says less is better, not by adding more. Almost no organisation passes that test.
• Assign ownership of total contact volume across brands. It is the least popular and most effective intervention available.

The gap is a measurement artefact, and that is good news

It would be easy to read the 82% against 28% finding as evidence that pharmaceutical companies do not care what their customers think. That reading is both unkind and unhelpful, and it does not survive contact with the people doing the work. Commercial teams in this industry are not indifferent to physicians; they are working from an information system that reports their own effort in exhaustive detail and the customer's response almost not at all. Given those inputs, an executive who reports satisfaction is reading the dashboard correctly.

That is genuinely good news, because measurement artefacts are fixable and cultural deficits are not. An organisation that instruments response time, produces total contact volume per physician across brands, and puts one customer-generated number in front of leadership every month will start behaving differently within two quarters — not because anyone gave a speech about customers, but because the information that reaches decision-makers has changed. Most of what is described as a mindset problem in this industry is a reporting problem wearing a mindset costume.

Start with the dashboard audit. Count the metrics. The number will make the argument for you.

Work with Multiplier AI

Customer centricity is mostly an organisational discipline, and the parts of it we can help with are specific. Personalisation only feels personal when the customer record is right — our GenAI Doctor Data Platform profiles physicians across more than 100 parameters with continuous verification, which is the precondition for relevance rather than a refinement of it. And relevance has to survive medical, legal and regulatory review — our Hyper Personalized Content Platform assembles approved content by cohort and behaviour and delivers it across email, WhatsApp and social with consent enforced at the point of sending. Published outcomes from Indian deployments include a minimum 120% increase in time spent in the doctor's cabin, a 37% increase in medical representative efficiency and a 35% increase in brand share of voice with doctor influencers. See our pharma solutions page, review our case studies, or book a demo — and bring the count from your dashboard audit.

Frequently Asked Questions For Customer Centricity in Pharma & Life Sciences